Eli Lilly and Co（LLY）のニュースとイベントLLYEli Lilly and Co

Eli Lilly's Foundayo Receives Marketing Authorization

On October 15, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Foundayo, intended for the treatment of type 2 diabetes mellitus and for weight management. The applicant for this medicinal product is Eli Lilly Nederland B.V. Foundayo will be available as 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg film-coated tablets. The active substance of Foundayo is orforglipron, a glucagon-like peptide 1 receptor agonist. By means of its action on these receptors, orforglipron improves glycaemic control and aids weight management through several different mechanisms. The benefits of Foundayo are its clinically relevant effect on glycaemic control in patients with type 2 diabetes. Foundayo has also a beneficial effect on body weight when used in combination with a healthy diet and physical activity. The most common side effects are gastrointestinal side effects such as nausea, vomiting and diarrhea.

U.S. Finds Poor Conditions at Two Chinese GLP-1 Drug Factories

Two Chinese factories making components for GLP-1 drugs in America were found to be in poor conditions, with U.S. inspectors noting black mold on equipment and "gross contamination" on the floors of one, Anna Edney of Bloomberg reports. Additionally, the inspectors caught employees trying to hide paperwork and evidence of bogus documentation. The two factories manufactured semaglutide and tirzepatide, the active ingredients in Novo Nordisk (NVO) and Eli Lilly's (LLY) GLP-1 drugs.